Preparation method of new polypeptide, and application of new polypeptide in treatment

A technology of pharmaceutical preparations and amino acids, applied in the field of medicine and biology, can solve problems such as side effects and toxicity

Inactive Publication Date: 2013-04-17
李萍
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But many of these anti-inflammatory drugs have side effects and toxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of new polypeptide, and application of new polypeptide in treatment
  • Preparation method of new polypeptide, and application of new polypeptide in treatment
  • Preparation method of new polypeptide, and application of new polypeptide in treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1: Chemical synthesis and purification of polypeptides:

[0020] Taking the amino acid sequence shown in SEQ ID No as an example, the polypeptide is chemically synthesized.

[0021] Synthesized by Fmoc solid-phase method:

[0022] Adopt solid-phase synthesis instrument, select the val-2 chlorotrityl resin of 0.5 gram as initial resin, add successively in the synthesis reaction tube:

[0023] Fmoc-arg(pbf)-OH, Fmoc-Gln(trt)-OH, Fmoc-lys(boc)-OH, Fmoc-cys(trt)-OH, Fmoc-phe-OH, Fmoc-arg(pbf)-OH , Fmoc-arg(pbf)-OH, Fmoc-arg(pbf)-OH, Fmoc-cys(trt)-OH, Fmoc-asn(trt)-OH, Fmoc-tyr(tbu)-OH, Fmoc-Ile- Oh

[0024] Add DIC / DMF solution, HOBT / DMF solution and DMF solution to the reagent bottle. Start the synthesis instrument and connect it to the computer, enter the synthesis program, and start the synthesis.

[0025] Compositing post-processing:

[0026] Take the resin out from the synthesis reaction column, put it into a glass container with a sintered glass filter a...

Embodiment 2

[0042] Embodiment 2: stability test

[0043] The polypeptide of the present invention was incubated at 40°C for 76 days and 120 days to test its stability. The stability test was determined by HPLC method. The concentration of polypeptide in aqueous solution is 0.2% (w / v): column, Kromasil100, 5u, 250x 4.6mm; mobile phase, water / acetonitrile solution of 0.1% trifluoroacetic acid (0 to 50vol.%), within 25 minutes Gradient elution, flow rate 1ml / min; detection: UV, 218nm.

[0044] For comparison, the free polypeptide and its monoacetate salt were used.

[0045] Table 1

[0046]

[0047] It can be shown from the data in Table 1 that the stability of the polypeptide of the present invention is very high. The solution still has more than 97% of the target substance after 120 days at 40°C.

Embodiment 3

[0048] Embodiment 3: the toxicity of polypeptide of the present invention

[0049] The acute toxicity of the polypeptide of the present invention is determined by intragastric administration and injection in mice.

[0050] Solution preparation:

[0051] Use 25 mg of the polypeptide of the present invention, add sterilized water to 20 ml, and prepare a solution with a concentration of 1.25 mg / ml for oral gavage.

[0052] Use 25 mg of the polypeptide of the present invention, add sterilized water to 10 ml, and prepare a solution with a concentration of 2.5 mg / ml for intraperitoneal injection.

[0053] Dosage Calculation:

[0054] The volume of oral gavage administration to mice is 40 ml / kg body weight, so the administration dose is: 1.25 mg / ml*40 ml / kg=50 mg / kg.

[0055]The volume of intraperitoneal injection in mice is 20ml / kg body weight, so the dosage is: 2.5mg / ml*20ml / kg=50mg / kg.

[0056] Take 80 healthy mice and divide them into four groups for experiment. After admini...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention discloses a new polypeptide with tissue protection activity. The invention discloses a sequence of the polypeptide, a structure of the polypeptide and a preparation method of the polypeptide. The polypeptide has good tissues and an organ protection function, and has a good cure effect for the inflammation of multiple tissues. The polypeptide is non-toxic and safe, thus having wide medicine and medical treatment prospects.

Description

technical field [0001] The invention belongs to the field of medical biotechnology. As a tissue protective polypeptide, the polypeptide of the invention can protect almost all organs and tissues of the body, especially for various tissue inflammations, and has good protection, treatment and healing effects. The invention relates to technologies such as solid-phase chemical synthesis of polypeptides, large-scale purification and freeze-drying of polypeptides, measurement of physical and chemical properties, and therapeutic applications. Background technique [0002] Inflammation is a defense-based pathological reaction produced by the body to various physical, chemical, biological and other harmful stimuli. A series of protective responses that occur when body tissues are damaged, centered on local blood vessels, typically characterized by redness, swelling, heat, pain, and dysfunction, and can be involved in removing foreign bodies and repairing tissues. [0003] Inflammati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06C07K7/08A61K38/08A61K38/10A61P29/00
Inventor 不公告发明人
Owner 李萍
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products